Methods for isolating and using a subset of cd8 t-cells that are resistant to inhibitors
OwnerRaymond M. Johnsoninventor
Life of this patent
Estimating the term…
Abstract
Methods for identifying a subset of CD8 T cells that is resistant to an inhibitor, specifically cyclosporine, rapamycin and/or tacrolimus, by detecting expression levels of human biomarkers are disclosed. The methods include determining whether a subset of certain CD8 T cells expresses elevated levels of Scin and/or Pla2g4a, with an elevated level indicative of proliferation of the identified CD8 T cells. Also disclosed are methods of diagnosing, monitoring and treating rheumatoid arthritis and transplant rejection, including determining and/or monitoring the expansion of a subset of CD8 T cells by measuring the level of expression of a biomarker in the population of the CD8 T cell subset.
Claims16
A method of identifying a subset of CD8 T cells that is resistant to an inhibitor, the method comprising the step of:
- determining whether a subset of CD8 T cells express an elevated level of at least one biomarker selected from the group consisting of Scin and Pla2g4a;
- wherein the existence of the elevated level of the at least one biomarker is indicative of the expansion of the CD8 T cells within the subset.
A method of diagnosing a condition in an individual, the method comprising the step of:
- determining if the individual has experienced an expansion of a subset of CD8 T cells that are resistant to an inhibitor selected from the group consisting of cyclosporine, tacrolimus and rapamycin.
A method for treating a condition in an individual comprising the step of:
- administering at least one therapeutically effective dose of at least one compound to the individual, the at least one compound capable of inhibiting proliferation of a subset of CD8 T cells from the individual that express aryl hydrocarbon receptor and are resistant to an inhibitor selected from the group consisting of a calcineurin inhibitor and a mTOR inhibitor;
- wherein the at least one compound comprises a calcineurin inhibitor and an aryl hydrocarbon receptor inhibitor.
Dependencies are inferred from the claim text.